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Implementation of the Verigene Gram-positive blood culture test led to reductions in time to acceptable antibiotic overall (1.9
versus 13.2 h, respectively; P  0.04) and time to appropriate antibiotic for patients with vancomycin-resistant Enterococcus (4.2
versus 43.7 h; P  0.006) and viridans group Streptococcus (0.2 versus 7.1 h; P  0.02).
Enterococci and streptococci are frequent causes of blood-stream infections (BSIs), which are associated with high mor-
tality when inappropriately treated (1). Timely initiation of ap-
propriate antibiotics is vital, as this permits effective targeting of
causative pathogens, decreased antimicrobial exposure, and pos-
sible cost savings. Therefore, rapid molecular tests are being used
with increasing frequency to facilitate antimicrobial stewardship
efforts. The FDA-cleared Verigene Gram-positive blood culture
test (BC-GP) (Nanosphere, Inc., Northbrook, IL) detects bacterial
DNA from blood cultures positive for Staphylococcus, Streptococ-
cus, Enterococcus, and Listeria spp. It also identifies mecA, which
confers methicillin resistance in staphylococci, and vanA and
vanB genes, which confer vancomycin resistance in enterococci.
We previously published a targeted treatment algorithm based
on BC-GP results (2). In this study, we evaluated clinical out-
comes associated with implementation of the BC-GP technology
and targeted treatment algorithm in patients with streptococcal
and enterococcal bacteremia in comparison with traditional mi-
crobiological methods. The primary outcome was time to appro-
priate antibiotic. Secondary outcomes included time to acceptable
antibiotic, time to culture clearance, length of stay (LOS), and
mortality.
This study, approved by the University of North Carolina In-
stitutional Review Board, used a quasiexperimental design com-
paring pre- and postintervention groups over 17 months. Patients
with blood cultures positive for Gram-positive cocci (GPC) in
pairs and/or chains were included. Subjects were excluded if they
had polymicrobial blood cultures, had positive cultures for Strep-
tococcus or Enterococcus spp. in both the case and control periods,
or were still hospitalized or if the positive blood culture was clas-
sified as a contaminant (i.e., one bottle positive for viridans group
streptococci [VGS]). Additionally, if a subject had a second blood
culture that was positive for the same organism within 14 days of
the first culture, the second culture was excluded.
In the preintervention period, Gram stain results were doc-
umented in the electronic medical record (EMR) system and
phoned to the patient’s primary team. After BC-GP implemen-
tation, Gram stain results were still phoned to the primary
team; however, if the stain was positive for GPC in pairs and/or
chains, the BC-GP test was performed. The result was commu-
nicated by microbiology laboratory staff to the pharmacist on
call, who referred to a treatment algorithm based on local sus-
ceptibility patterns and clinical guidelines to recommend
targeted therapy (2). BC-GP results were confirmed by conven-
tional microbiological methods (matrix-assisted laser de-
sorption ionization–time of flight mass spectrometry [MALDI-
TOF MS] and Vitek2; bioMérieux, Durham, NC).
The EMR was used to determine the time to appropriate and
acceptable therapy. Appropriate therapy was defined as an antibi-
otic delineated in the algorithm. Acceptable therapy was defined
as an antibiotic that provided adequate activity against the organ-
ism identified but was not the therapy of choice. If appropriate or
acceptable therapy was received before the positive Gram stain,
the time was 0 days. These data were collected retrospectively by
systematic chart review.
Univariate analysis was performed using a t test for continuous
variables and a Pearson 2 test for categorical variables. P values
were not calculated if there were fewer than 5 subjects in either the
pre- or post-BC-GP group. A two-tailed P value of 0.05 was
considered significant (SAS v9.3; SAS Institute, Cary, NC).
In the study period, 205 subjects were identified. After exclu-
sion criteria were applied, 74 cases and 65 controls remained.
Baseline demographics, laboratory values, and risk factors for bac-
teremia were not different between groups (Table 1). Organisms
identified by the BC-GP test and traditional culture were not sta-
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tistically different, with VGS and vancomycin-susceptible Entero-
coccus faecalis (VSE) being the most common (Table 2).
Mean time to appropriate antibiotic was numerically but not
statistically shorter in the post-BC-GP group than the pre-BC-GP
group (4.5 versus 10.2 h, respectively; P  0.07). The largest dif-
ference was seen in patients with vancomycin-resistant Enterococ-
cus (VRE), where the time to appropriate antibiotic was 4.2 versus
43.7 h, respectively (P  0.006). A significant difference was also
seen in patients with VGS (0.2 versus 7.1 h; P  0.02). No signif-
icant difference was observed in patients with VSE (0.7 versus
TABLE 1 Baseline demographics
Characteristica
Value for group
P valuePre-BC-GP (n  65) Post-BC-GP (n  74)
Age [mean (SD)] 54.5 (22.0) 57.3 (20.8) 0.43
No. (%) with malignancy 27 (41.5) 32 (43.2) 0.84
Solid organ tumor 14 (21.5) 21 (28.4) 0.35
Hematologic malignancy 14 (21.5) 14 (18.9) 0.70
HSCT 8 (12.3) 3 (4.1) 0.07
No. (%) with solid organ transplant recipient 2 (3.1) 4 (5.4) 0.50
No. (%) diabetic 17 (26.2) 28 (37.8) 0.14
No. (%) HIV positive 1 (1.5) 2 (2.7) 0.64
No. (%) with recent surgery within 1 mo 12 (18.5) 11 (14.9) 0.57
No. (%) with systemic steroids 8 (12.3) 10 (13.5) 0.83
No. (%) with immunomodulating agentsb 13 (20.0) 13 (17.6) 0.71
No. (%) with dialysis 6 (9.2) 6 (8.1) 0.81
No. (%) neutropenic (ANC  0.5) 13 (20.0) 11 (14.9) 0.42
Mean (SD) ANC for neutropenic patients 0.08 (0.19) 0.13 (0.18)
No. (%) with renal failure (serum creatinine  2) 17 (26.2) 16 (21.6) 0.53
No. (%) with hepatic failure 9 (13.9) 6 (8.1) 0.28
No. (%) in intensive care unit 6 (9.2) 10 (13.5) 0.43
No. (%) with TPN 6 (9.2) 3 (4.1) 0.22
No. (%) with endocarditis proven by ECHO 4 (8.9) 9 (18.0) 0.20
No. (%) with central catheter 28 (43.1) 26 (35.1) 0.34
a HSCT, hematopoietic stem cell transplant; TPN, total parenteral nutrition.
b Immunomodulating agents include tacrolimus, mycophenolate, cyclosporine, azathioprine, sirolimus, or other transplant biologics.
TABLE 2 Organisms identified by culture
Organism
No. (%) in group
P valueBefore BC-GP (n  65) After BC-GP (n  74)
Group A Streptococcus 3 (4.6) 1 (1.4) 0.25
Group B Streptococcus 3 (4.6) 11 (14.9) 0.05
Streptococcus anginosus group 2 (3.1) 5 (6.8) 0.32
Viridans group Streptococcus 17 (26.2) 15 (20.3) 0.41
Streptococcus pneumoniae 8 (12.3) 10 (13.5) 0.83
Other Streptococcus spp. 6 (9.2) 4 (5.4) 0.38
Enterococcus faecalis
Vancomycin susceptible 14 (21.5) 15 (20.3) 0.85
Vancomycin resistant 0 (0) 0 (0) NAa
Enterococcus faecium
Vancomycin susceptible 4 (6.2) 4 (5.4) 0.85
Vancomycin resistant 7 (10.8) 7 (9.5) 0.80
Other 1 (1.5) 2 (2.7) 0.64
a NA, not applicable.
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3.2 h; P  0.15). For time to acceptable antibiotic, the overall
mean time was 11 h shorter in the post-BC-GP group (1.9 versus
13.2 h, respectively; P  0.04) (Table 3).
Nonsignificant decreases in patient outcomes such as time to
culture clearance and LOS were observed in the post-BC-GP
group. There was no difference in mortality, which was approxi-
mately 10% in both groups (P  0.82).
To our knowledge, this is the first study investigating the clin-
ical impact of a rapid molecular assay on patients with streptococ-
cal bacteremia. Two prior studies evaluated the impact of rapid
detection methods on patients with enterococcal bacteremia (3,
4). Forrest and colleagues (3) examined the impact of the PNA
FISH (peptide nucleic acid fluorescence in situ hybridization) test
(AdvanDx, Inc., Woburn, MA) on outcomes in patients with en-
terococcal bacteremia and found that patients in the postinterven-
tion group received appropriate therapy significantly faster, re-
sulting in decreased mortality (26% versus 45%; P  0.04) but no
difference in LOS. Sango and colleagues (4) also investigated the
impact of the BC-GP assay on patients with enterococcal bactere-
mia. A significant difference was observed in time to appropriate
therapy in patients with VRE (31.6 versus 62.7 h; P  0.001) but
not VSE (18.6 versus 40.2 h; P  0.1145). Total hospital LOS was
not improved by the test (43.5 versus 22.2 days; P  0.141) when
deceased patients were removed from the analysis.
Explanations for the lack of significant difference in the pri-
mary outcome include the fact that our institution is an academic
TABLE 3 Mean time to appropriate and acceptable antibiotic
Parameter
Mean (SD) value for group
P value
n
Pre-BC-GP Post-BC-GP Pre-BC-GP Post-BC-GP
No. (%) that never received appropriate antibiotic 11 (16.9) 8 (10.8) 0.30
Mean time to appropriate antibiotic (h), by organism 10.2 (19.8) 4.5 (14.4) 0.07 54 66
Group A Streptococcus 17.0 (23.8) 6.6 (NAc) NA 2 1
Group B Streptococcus 0 (0) 15.8 (20.3) NA 2 8
Streptococcus anginosus group 2.4 (NA) 50.9 (65.4) NA 1 2
Viridans group Streptococcus 7.1 (10.7) 0.2 (0.5) 0.02 12 14
Streptococcus pneumoniae 1.1 (1.4) 1.4 (3.9) 0.85 6 10
Other Streptococcus spp. 10.3 (21.9) 0.4 (0.3) NA 6 3
E. faecalis
Vancomycin susceptible 2.2 (6.3) 0.7 (1.3) 0.35 14 15
Vancomycin resistant NA NA NA 0 0
E. faecium
Vancomycin susceptible 7.4 (10.6) 0.9 (0.9) NA 3 4
Vancomycin resistant 43.7 (31.5) 4.2 (2.8) 0.006 7 7
Mean time to appropriate antibiotic (h), by treatment group
Penicillin susceptible Streptococcusa 7.3 (14.9) 21.3 (30.6) 0.35 5 11
Vancomycin susceptible Streptococcusb 6.4 (13.1) 0.7 (2.4) 0.03 24 27
Vancomycin susceptible Enterococcus 3.2 (7.1) 0.7 (1.2) 0.15 17 19
Vancomycin resistant Enterococcus 43.7 (31.5) 4.2 (2.8) 0.006 7 7
Mean time to appropriate antibiotic (h) by genus
All Streptococcus spp. 6.6 (13.1) 6.7 (18.6) 0.98 29 38
All Enterococcus spp. 15.0 (25.4) 1.7 (2.3) 0.01 24 26
No. (%) that never received acceptable antibiotic 1 (1.5) 1 (1.4) 0.93
Mean time to acceptable antibiotic (h), by organism 13.2 (46.0) 1.9 (7.2) 0.04 64 73
Group A Streptococcus 21.1 (18.2) 5.6 (NA) NA 3 1
Group B Streptococcus 0 (0) 6.3 (17.6) NA 3 11
S. anginosus group 1.2 (1.7) 0.9 (2.1) NA 2 5
Viridans group Streptococcus 8.6 (11.7) 0.1 (0.3) 0.01 16 14
Streptococcus pneumoniae 0.6 (1.3) 1.3 (4.0) 0.66 8 10
Other Streptococcus spp. 1.2 (2.4) 0 (0) NA 6 4
Enterococcus faecalis
Vancomycin susceptible 2.2 (6.3) 0.7 (1.3) 0.35 14 15
Vancomycin resistant NA NA NA 0 0
Enterococcus faecium
Vancomycin susceptible 94.7 (174.7) 0.9 (0.9) NA 4 4
Vancomycin resistant 30.8 (26.6) 4.2 (2.8) 0.02 7 7
a Group A Streptococcus, group B Streptococcus, and S. anginosus group.
b Viridans group Streptococcus spp. (not S. anginosus group), S. pneumoniae, and other Streptococcus spp.
c NA, not applicable.
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medical center that provides care for many immunocompromised
populations; therefore, it may not have been feasible to narrow
empirical antimicrobial therapy despite targeted culture results.
Additionally, providers may have opted to wait for final confirma-
tion of results.
Limitations of the study include that it was conducted at a
single center with a small sample size and was limited by the num-
ber of cases that occurred. Many subjects were excluded due to
polymicrobial blood cultures (n  62). Several patients were on
appropriate or acceptable therapy before the BC-GP result due to
empirical treatment. The study does not control for the steward-
ship intervention itself; therefore, it is impossible to know if dif-
ferences observed were a product of the technology, stewardship,
or both.
In conclusion, minimizing time to targeted antimicrobial ther-
apy may reduce exposure to broad-spectrum antibiotics and de-
crease costs. Utilization of rapid molecular assays, such as the
BC-GP test, in conjunction with antimicrobial stewardship pro-
grams, can decrease the time to targeted therapy, especially in
patients with VRE.
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